Secondary Logo

Journal Logo

October 2009 - Volume 19 - Issue 10
pp: 735-832

Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment

Liou, Ying-Jay; Chen, Tai-Jui; Tsai, Shih-Jen; More

Pharmacogenetics and Genomics. 19(10):735-741, October 2009.

Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats

Grandemange, Agnes; Kohn, Michael Hans; Lasseur, Romain; More

Pharmacogenetics and Genomics. 19(10):742-750, October 2009.

Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians

Boeckmann, Lars; Schirmer, Markus; Rosenberger, Albert; More

Pharmacogenetics and Genomics. 19(10):760-769, October 2009.

Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1

Ha Choi, Ji; Wah Yee, Sook; Kim, Mee J.; More

Pharmacogenetics and Genomics. 19(10):770-780, October 2009.

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

Zhang, Jieying Eunice; Jorgensen, Andrea L.; Alfirevic, Ana; More

Pharmacogenetics and Genomics. 19(10):781-789, October 2009.

Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders

Hammer, Christian; Kapeller, Johannes; Endele, Max; More

Pharmacogenetics and Genomics. 19(10):790-799, October 2009.

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

Jorgensen, Andrea L.; Al-Zubiedi, Sameh; Zhang, Jieying Eunice; More

Pharmacogenetics and Genomics. 19(10):800-812, October 2009.

Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians

Sharma, Shruti; Das, Mitashree; Kumar, Ashok; More

Pharmacogenetics and Genomics. 19(10):823-828, October 2009.